Liver in haematological disorders

Best Practice and Research: Clinical Gastroenterology

Volumn 27, Issue 4, 2013, Pages 513-530

  Pieri, Giulia ^a   Theocharidou, Eleni ^a   Burroughs, Andrew K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Budd Chiari syndrome; Myeloproliferative disorders; Portal vein thrombosis; Post transplant lymphoproliferative disorders; Sinusoidal obstruction syndrome

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALKYLATING AGENT; ALTEPLASE; ANTINEOPLASTIC AGENT; ANTITHROMBIN III; ANTIVITAMIN K; AZATHIOPRINE; BLOOD CLOTTING FACTOR 5 LEIDEN; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; ENOXAPARIN; JANUS KINASE 2; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; MERCAPTOPURINE; MYELOABLATIVE AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROTEIN C; PROTEIN S; PROTHROMBIN; RITUXIMAB; STREPTOKINASE; TIOGUANINE; UNINDEXED DRUG; UROKINASE;

ADOPTIVE IMMUNOTHERAPY; ANTICOAGULANT THERAPY; ARTICLE; BUDD CHIARI SYNDROME; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE CLASSIFICATION; DOPPLER ECHOGRAPHY; DRUG MEGADOSE; EPSTEIN BARR VIRUS INFECTION; EXTRAMEDULLARY HEMATOPOIESIS; FIBRINOLYTIC THERAPY; GENE MUTATION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC ANEMIA; HEMOPHAGOCYTIC SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATOMEGALY; HUMAN; HYPERHOMOCYSTEINEMIA; INTERNATIONAL NORMALIZED RATIO; LANGERHANS CELL HISTIOCYTOSIS; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; LYMPHOMA; MICROTHROMBUS; MYELOABLATIVE CONDITIONING; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; POLYCYTHEMIA VERA; PORTAL VEIN THROMBOSIS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMARY HEPATIC LYMPHOMA; RISK FACTOR; SPLANCHNIC BLOOD FLOW; SPLANCHNIC VEIN THROMBOSIS; SPLENIC MARGINAL ZONE LYMPHOMA; SYSTEMIC MASTOCYTOSIS; THROMBECTOMY; THROMBOCYTHEMIA; THROMBOPHILIA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VEIN THROMBOSIS; VIRUS CARCINOGENESIS; VIRUS HEPATITIS; VIRUS REACTIVATION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84885179833     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2013.06.012     Document Type: Review

References (91)

1. Senzolo M, Cholongitas EC, Patch D, Burroughs AK. Update on the classification, assessment of prognosis and therapy of Budd-Chiari syndrome. Nat Clin Pract Gastroenterol Hepatol 2005;2(4):182-90 (Pubitemid 40812503)
2. Darwish MS, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009;151(3):167-75
3. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009;49(5):1729-64
4. Valla D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985;103(3):329-34 (Pubitemid 15236564)
5. Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012;120(25):4921-8
6. Jadli A, Kulkarni B, Ghosh K, Shetty S. Non conventional mutations associated with myeloproliferative disorders are absent in splanchnic venous thrombosis cases. Liver Int 2012;32(10):1596-7
7. Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M, et al. JAK2V617F mutation for the early diagnosis of Phmyeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009;113(22):5617-23
8. Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 2009;113(21):5246-9
9. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009;41(4):446-9
10. Smalberg JH, Koehler E, Darwish MS, Plessier A, Seijo S, Trebicka J, et al. The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood 2011;117(15):3968-73
11. Colaizzo D, Amitrano L, Tiscia GL, Grandone E, Guardascione MA, Margaglione M. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood 2007;110(7):2768-9 (Pubitemid 47523205)
12. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22(1):14-22
13. De SV, Voso MT, Chiusolo P, Paciaroni K, Bizzi B, Leone G. Prevalence of mutated factor V ARG506 to GLN in Italians. Thromb Haemost 1997;77(1):216-7
14. Bosy-Westphal A, Ruschmeyer M, Czech N, Oehler G, Hinrichsen H, Plauth M, et al. Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. Am J Clin Nutr 2003; 77(5):1269-77 (Pubitemid 44858446)
15. Li XM, Wei YF, Hao HL, Hao YB, He LS, Li JD, et al. Hyperhomocysteinemia and the MTHFR C677T mutation in Budd-Chiari syndrome. Am J Hematol 2002;71(1):11-4
16. Vaya A, Plume G, Bonet E, Carrasco P, Morales-Suarez-Varela MM. Hyperhomocysteinemia and the methylene tetrahydrofolate reductase C677T mutation in splanchnic vein thrombosis. Eur J Haematol 2011;86(2):167-72
17. Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore) 1997;76(2):63-93 (Pubitemid 27157663)
18. Ziakas PD, Poulou LS, Rokas GI, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost 2007;5(3):642-5 (Pubitemid 46680714)
19. Melear JM, Goldstein RM, Levy MF, Molmenti EP, Cooper B, Netto GJ, et al. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation 2002;74(8):1090-5 (Pubitemid 35216101)
20. Mentha G, Giostra E, Majno PE, BechsteinWO, Neuhaus P, O?Grady J, et al. Liver transplantation for Budd-Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol 2006;44(3):520-8 (Pubitemid 43227876)
21. Webster GJ, Burroughs AK, Riordan SM. Review article: portal vein thrombosis - new insights into aetiology and management. Aliment Pharmacol Ther 2005;21(1):1-9 (Pubitemid 40175338)
22. Gurakan F, Eren M, Kocak N, Yuce A, Ozen H, Temizel IN, et al. Extrahepatic portal vein thrombosis in children: etiology and long-term follow-up. J Clin Gastroenterol 2004;38(4):368-72 (Pubitemid 38393075)
23. Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, Der Meer FJ, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000;96(7):2364-8
24. Hoekstra J, Bresser EL, Smalberg JH, Spaander MC, Leebeek FW, Janssen HL. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J Thromb Haemost 2011;9(11):2208-14
25. Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. A metaanalysis. Thromb Haemost 2008;99(4):675-82 (Pubitemid 351694223)
26. Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D?Andrea G, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000;31(2):345-8 (Pubitemid 30078598)
27. Raffa S, Reverter JC, Seijo S, Tassies D, Abraldes JG, Bosch J, et al. Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis. Clin Gastroenterol Hepatol 2012;10(1):72-8
28. Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005;41(3):603-8 (Pubitemid 40289509)
29. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010;31(3):366-74
30. Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011;9(9):1713-23
31. Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol 2012;57(1):203-12
32. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005;54(5):691-7 (Pubitemid 40559257)
33. Monroe DM, Hoffman M. The coagulation cascade in cirrhosis. Clin Liver Dis 2009;13(1):1-9
34. Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010;8(9):1994-2000
35. Ponziani FR, Zocco MA, Garcovich M, D?Aversa F, Roccarina D, Gasbarrini A. What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective. World J Gastroenterol 2012;18(36):5014-20
36. Violi F, Ferro D, Basili S, Lionetti R, Rossi E, Merli M, et al. Ongoing prothrombotic state in the portal circulation of cirrhotic patients. Thromb Haemost 1997;77(1):44-7 (Pubitemid 27064966)
37. Hoekstra J, Janssen HL. Vascular liver disorders (II): portal vein thrombosis. Neth J Med 2009;67(2):46-53
38. Sogaard KK, Astrup LB, Vilstrup H, Gronbaek H. Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol 2007;7:34
39. D?Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003;38(3):599-612 (Pubitemid 37052147)
40. Janssen HL, Wijnhoud A, Haagsma EB, van Uum SH, van Nieuwkerk CM, Adang RP, et al. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut 2001;49(5):720-4 (Pubitemid 32989212)
41. Englesbe MJ, Kubus J, Muhammad W, Sonnenday CJ, Welling T, Punch JD, et al. Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl 2010;16(1):83-90
42. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012;143(5):1253-60
43. Senzolo M, Tibbals J, Cholongitas E, Triantos CK, Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 2006;23(6):767-75 (Pubitemid 43344596)
44. Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010;44(6):448-51
45. D?Avola D, Bilbao JI, Zozaya G, Pardo F, Rotellar F, Inarrairaegui M, et al. Efficacy of transjugular intrahepatic portosystemic shunt to prevent total portal vein thrombosis in cirrhotic patients awaiting for liver transplantation. Transplant Proc 2012; 44(9):2603-5
46. Luca A, Miraglia R, Caruso S, Milazzo M, Sapere C, Maruzzelli L, et al. Short-and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut 2011;60(6):846-52
47. Senzolo M, Burra P, Patch D, Burroughs AK. Tips for portal vein thrombosis (pvt) in cirrhosis: not only unblocking a pipe. J Hepatol 2011;55(4):945-6
48. Han G, Qi X, He C, Yin Z, Wang J, Xia J, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol 2011;54(1):78-88
49. Lendoire J, Raffin G, Cejas N, Duek F, Barros SP, Trigo P, et al. Liver transplantation in adult patients with portal vein thrombosis: risk factors, management and outcome. HPB (Oxford) 2007;9(5):352-6 (Pubitemid 47604635)
50. Handa P, Crowther M, Douketis JD. Portal vein thrombosis: a clinician-oriented and practical review. Clin Appl Thromb Hemost 2013
51. Cliffe ST, Bloch DB, Suryani S, Kamsteeg EJ, Avery DT, Palendira U, et al. Clinical, molecular, and cellular immunologic findings in patients with SP110-associated veno-occlusive disease with immunodeficiency syndrome. J Allergy Clin Immunol 2012;130(3):735-42
52. Campos-Varela I, Castells L, Dopazo C, Perez-Lafuente M, Allende H, Len O, et al. Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. Liver Transpl 2012;18(2):201-5
53. Plessier A, Rautou PE, Valla DC. Management of hepatic vascular diseases. J Hepatol 2012;56(Suppl. 1):S25-38
54. Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, et al. Transjugular liver biopsy-indications, adequacy, quality of specimens, and complications-a systematic review. J Hepatol 2007;47(2):284-94 (Pubitemid 47021258)
55. Richardson PG, Ho VT, Cutler C, Glotzbecker B, Antin JH, Soiffer R. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant 2013;19(Suppl. 1):S88-90
56. Senzolo M, Germani G, Cholongitas E, Burra P, Burroughs AK. Veno occlusive disease: update on clinical management. World J Gastroenterol 2007;13(29):3918-24 (Pubitemid 47272486)
57. Hagglund H, Ringden O, Ericzon BG, Duraj F, Ljungman P, Lonnqvist B, et al. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. Transplantation 1996;62(8):1076-80 (Pubitemid 26376655)
58. Rosen HR, Martin P, Schiller GJ, Territo M, Lewin DN, Shackleton CR, et al. Orthotopic liver transplantation for bonemarrow transplant-associated veno-occlusive disease and graft-versus-host disease of the liver. Liver Transpl Surg 1996;2(3):225-32 (Pubitemid 26151378)
59. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006;6(5 Pt 1): 1017-24 (Pubitemid 44356653)
60. Lo RC, Chan SC, Chan KL, Chiang AK, Lo CM, Ng IO. Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study. J Clin Pathol 2013;66(5):392-8
61. Kamdar KY, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant 2011;16(3):274-80
62. Ng SB, Khoury JD. Epstein-Barr virus in lymphoproliferative processes: an update for the diagnostic pathologist. Adv Anat Pathol 2009;16(1):40-55
63. Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995;20(5):1346-53
64. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4(2):222-30 (Pubitemid 38248525)
65. Dharnidharka VR. Post-transplant lymphoproliferative disease: association with induction therapy? Drugs 2006;66(4): 429-38
66. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009;114(19):4002-8
67. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 2013;59:169-77
68. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011;22(5): 1170-80
69. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148(7):519-28 (Pubitemid 351665421)
70. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27(4):605-11
71. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57(1):167-85
72. Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 2012;57(6):1177-85
73. Banerjee S, Owen C, Chopra S. Sickle cell hepatopathy. Hepatology 2001;33(5):1021-8 (Pubitemid 32378197)
74. Omata M, Johnson CS, Tong M, Tatter D. Pathological spectrum of liver diseases in sickle cell disease. Dig Dis Sci 1986; 31(3):247-56 (Pubitemid 16123969)
75. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993;329(12):840-4 (Pubitemid 23267211)
76. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009;373(9665):759-67
77. Korkmaz H, Bugdaci MS, Temel T, Dagli M, Karabagli P. Autoimmune hepatitis-primary biliary cirrhosis overlap syndrome concomitant with immune hemolytic anemia and immune thrombocytopenic purpura (Evans syndrome). Clin Res Hepatol Gastroenterol 2013;37(2):e45-50
78. Vassiliadis T, Mpoumponaris A, Vakalopoulou S, Giouleme O, Gkissakis D, Grammatikos N, et al. Spur cells and spur cell anemia in hospitalized patients with advanced liver disease: incidence and correlation with disease severity and survival. Hepatol Res 2010;40(2):161-70
79. Souto P, Romaozinho JM, Figueiredo P, Ferreira M, Sousa I, Camacho E, et al. Severe acute liver failure as the initial manifestation of haematological malignancy. Eur J Gastroenterol Hepatol 1997;9(11):1113-5 (Pubitemid 27488878)
80. Walz-Mattmuller R, Horny HP, Ruck P, Kaiserling E. Incidence and pattern of liver involvement in haematological malignancies. Pathol Res Pract 1998;194(11):781-9 (Pubitemid 28525924)
81. Forbes GM, Davies JM, Herrmann RP, Collins BJ. Liver disease complicating bone marrow transplantation: a clinical audit. J Gastroenterol Hepatol 1995;10(1):1-7
82. Hubscher SG, Lumley MA, Elias E. Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma. Hepatology 1993;17(1):70-7 (Pubitemid 23027387)
83. Watterson J, Priest JR. Jaundice as a paraneoplastic phenomenon in a T-cell lymphoma. Gastroenterology 1989;97(5): 1319-22 (Pubitemid 19258720)
84. Birrer MJ, Young RC. Differential diagnosis of jaundice in lymphoma patients. Semin Liver Dis 1987;7(3):269-77
85. Chim CS, Choy C, Ooi GC, Liang R. Primary hepatic lymphoma. Leuk Lymphoma 2001;40(5-6):667-70 (Pubitemid 32303256)
86. Scoazec JY, Degott C, Brousse N, Barge J, Molas G, Potet F, et al. Non-Hodgkin's lymphoma presenting as a primary tumor of the liver: presentation, diagnosis and outcome in eight patients. Hepatology 1991;13(5):870-5
87. Mican JM, Di Bisceglie AM, Fong TL, Travis WD, Kleiner DE, Baker B, et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 1995;22(4 Pt 1):1163-70
88. Iwai M, Kashiwadani M, Okuno T, Takino T, Koshikawa T. Cholestatic liver disease in a 20-yr-old woman with histiocytosis X. Am J Gastroenterol 1988;83(2):164-8 (Pubitemid 18063508)
89. Zandi P, Panis Y, Debray D, Bernard O, Houssin D. Pediatric liver transplantation for Langerhans? cell histiocytosis. Hepatology 1995;21(1):129-33
90. Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol 2010;6(1):137-54
91. Wright G, Wilmore S, Makanyanga J, McKerrell T, Watkins J, Patch D, et al. Liver transplant for adult hemophagocytic lymphohistiocytosis: case report and literature review. Exp Clin Transpl 2012;10(5):508-12